Skip to main content
OpenTrials
Completed

NCT Number: NCT01333007

An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer

This observational study will evaluate modality, efficacy and safety of Avastin (bevacizumab) as first-line treatment in combination with chemotherapy in patients with inoperable advanced, metastatic or recurrent non-squamous non-small cell lung cancer in clinical practice. Data will be collected for each patient for 18 months from initiation of Avastin therapy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Abbeville, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients, >/= 18 years of age
  • Inoperable advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC)
  • Treating physician's decision to initiate first-line Avastin treatment

Exclusion criteria

  • Participation in a clinical trial evaluating anti-cancer therapies

Treatment and study plan

Primary outcomes

  1. Progression-free survival

    Time frame: 18 months

Secondary outcomes

  1. Clinical (diagnosis, therapies, comorbidity) and demographic characteristics of patients initiated on Avastin treatment

    Time frame: 18 months

  2. Modality of treatment with Avastin (dose, duration, associated chemotherapy)

    Time frame: 18 months

  3. Overall survival

    Time frame: 18 months

  4. Safety: Incidence of adverse events

    Time frame: 18 months

  5. Quality of Life: Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire

    Time frame: 18 months

  6. Treatment of non-squamous NSCLC in clinical practice

    Time frame: 18 months

Sponsors and collaborators

Lead sponsor

Hoffmann-La Roche

Industry

Registry information

Official study title

A Cohort Study of First-line Treatment of Patients With Unresectable Advanced (Stage IIIB), Metastatic (Stage IV) or Recurrent Non Squamous Non-small Cell Lung Cancer (NSCLC), Starting a Treatment With Bevacizumab (Avastin®) in Combination With Chemotherapy.

Important dates

Study start
2010
Primary completion
2013
Study completion
2013
First posted
Apr 11, 2011
Registry last updated
Nov 2, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.